A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome.

Une, Minami; Fujiwara, Ryo; Ueki, Arisa; Oki, Ryosuke; Urasaki, Tetsuya; Inamura, Kentaro; Takahashi, Shunji; Yonese, Junji; Yuasa, Takeshi

Une, Minami; Fujiwara, Ryo; Ueki, Arisa; Oki, Ryosuke; Urasaki, Tetsuya; Inamura, Kentaro; Takahashi, Shunji; Yonese, Junji; Yuasa, Takeshi.

Afiliação

Une M; Department of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Fujiwara R; Department of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Ueki A; Department of Clinical Genetic Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Oki R; Department of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Urasaki T; Department of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Inamura K; Department of Pathology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Takahashi S; Department of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Yonese J; Department of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Yuasa T; Department of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.

IJU Case Rep ; 6(5): 286-289, 2023 Sep.

Article em En | MEDLINE | ID: mdl-37667764

Palavras-chave

LiFraumeni syndrome; TP53 pathogenic variant; advanced urothelial cancer; avelumab; immune checkpoint inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Idioma: En Revista: IJU Case Rep Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google